Results 41 to 50 of about 590 (119)

Phenotypes and clinical outcomes in children with moderate‐to‐severe atopic dermatitis across diverse ancestries: a Spanish multicenter observational study and cluster analysis (AD‐SKINS Project)

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Atopic dermatitis (AD) has a highly variable clinical phenotype and ancestry can contribute to this heterogeneity. This study aims to identify clinical phenotypes of AD in children from diverse ancestry groups, evaluate clinical outcomes and response to treatment, and define phenotypic clusters with potential relevance.
Eugeni Prat‐Colilles, Adrià Plana‐Pla, Asunción Vicente, Eulàlia Baselga, Helena Iznardo, Esther Roé, Miquel Casals‐Andreu, Maria Sin‐Soler, Josep A. Pujol‐Montcusí, Maria del Mar Cordellat‐Martínez, Xavier Soria‐Gili, Maria del Mar Tapias‐Terré, Marta Bertolin‐Colilla, Nidia Planella‐Fontanillas, Laura Marques‐Martín, Mónica Munera‐Campos, Maria Fabregat‐Pratdepadua, Carolina S. Prat‐Torres, Marta Ivars, Luisa F. Montenegro‐Morillo, Isabel Bielsa‐Marsol, Jose‐Manuel Carrascosa‐Carrillo   +21 more
wiley   +1 more source

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease

Journal of Ophthalmic Inflammation and Infection
Background Dupilumab and tralokinumab are interleukin-binding monoclonal antibodies used to treat systemic atopic disease. Use of these medications in management of atopic dermatitis (AD) is known to cause conjunctivitis.
Nenita Maganti, Samuel A. Whittier, Evan J. Warner   +2 more
doaj   +1 more source

A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults

, 2023
Introduction: Atopic dermatitis (AD) is a chronic, intensely pruritic disease associated with significant patient burden. Recent advancements in AD pathogenesis have expanded its therapeutics pipeline.
Sechi, Andrea, Tartaglia, Jacopo, Pezzolo, Elena, Naldi, Luigi   +3 more
core   +1 more source

Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis

Journal of Dermatological Treatment, 2023
Purpose: Although psoriasis and atopic dermatitis (AD) were for decades considered to be opposing diseases, it is now known that these skin conditions can coexist or even overlap in the same individual. Especially when using modern drugs with targeted IL
Galina Balakirski, Sven-Niklas Burmann, Silke C. Hofmann, Alexander Kreuter   +3 more
doaj   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison

Dermatology and Therapy
Introduction Both tralokinumab and dupilumab have shown efficacy in atopic dermatitis (AD) with moderate-to-severe hand involvement in double-blind phase 3 trials.
April Armstrong, Leon Kircik, Andrei Metelitsa, Richard B. Warren, Adrian Rodriguez, Sebastian Volc, Naiem Issa, Raj Chovatiya, Rie von Eyben, Teodora Festini, Pierre Johansen, Benjamin Ehst   +11 more
doaj   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, Konstantin Popovic, Haq Nawaz, Qian Li, Vivek Purohit, Andreas Wollenberg   +14 more
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1831-1839, November 2026.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

Allergy, Volume 81, Issue 10, Page 3599-3607, October 2026.
Atopic dermatitis (AD) is characterized by microbial dysbiosis. This study aimed to evaluate the effects of abrocitinib, a JAK1‐selective inhibitor, on the skin microbiome and its potential associations with clinical outcomes in patients with AD. Abrocitinib treatment was associated with increased skin microbial diversity and decreased Staphylococcus ...
Madeline Kim, Ester Del Duca, Joel Correa Da Rosa, Juliana Pulsinelli, Yeriel Estrada, Dan Xu, Gary Chan, Allshine Chen, Erman Güler, Karen Page, Emma Guttman‐Yassky   +10 more
wiley   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1626-1647, October 2026.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source